LhARA: The Laser-hybrid Accelerator for Radiobiological Applications

Galen Aymar, Tobias Becker, Stewart Boogert, Marco Borghesi, Robert Bingham, Ceri Brenner, Philip N. Burrows, Oliver C. Ettlinger, Titus Dascalu, Stephen Gibson, Timothy Greenshaw, Sylvia Gruber, Dorothy Gujral, Claire Hardiman, Jonathan Hughes, W. G. Jones, Karen Kirkby, Ajit Kurup*, Jean Baptiste Lagrange, Kenneth LongWayne Luk, John Matheson, Paul McKenna, Ruth McLauchlan, Zulfikar Najmudin, Hin T. Lau, Jason L. Parsons, Jaroslaw Pasternak, Juergen Pozimski, Kevin Prise, Monika Puchalska, Peter Ratoff, Giuseppe Schettino, William Shields, Susan Smith, John Thomason, Stephen Towe, Peter Weightman, Colin Whyte, Rachel Xiao

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
149 Downloads (Pure)


The “Laser-hybrid Accelerator for Radiobiological Applications,” LhARA, is conceived as a novel, flexible facility dedicated to the study of radiobiology. The technologies demonstrated in LhARA, which have wide application, will be developed to allow particle-beam therapy to be delivered in a new regimen, combining a variety of ion species in a single treatment fraction and exploiting ultra-high dose rates. LhARA will be a hybrid accelerator system in which laser interactions drive the creation of a large flux of protons or light ions that are captured using a plasma (Gabor) lens and formed into a beam. The laser-driven source allows protons and ions to be captured at energies significantly above those that pertain in conventional facilities, thus evading the current space-charge limit on the instantaneous dose rate that can be delivered. The laser-hybrid approach, therefore, will allow the radiobiology that determines the response of tissue to ionizing radiation to be studied with protons and light ions using a wide variety of time structures, spectral distributions, and spatial configurations at instantaneous dose rates up to and significantly beyond the ultra-high dose-rate “FLASH” regime. It is proposed that LhARA be developed in two stages. In the first stage, a programme of in vitro radiobiology will be served with proton beams with energies between 10 and 15 MeV. In stage two, the beam will be accelerated using a fixed-field alternating-gradient accelerator (FFA). This will allow experiments to be carried out in vitro and in vivo with proton beam energies of up to 127 MeV. In addition, ion beams with energies up to 33.4 MeV per nucleon will be available for in vitro and in vivo experiments. This paper presents the conceptual design for LhARA and the R&D programme by which the LhARA consortium seeks to establish the facility.

Original languageEnglish
Article number567738
JournalFrontiers in Physics
Publication statusPublished - 29 Sep 2020


  • fixed-field alternating-gradient acceleration
  • ion beam therapy
  • laser-driven acceleration
  • novel acceleration
  • plasma lens
  • proton beam therapy (PBT)
  • radiobiology

ASJC Scopus subject areas

  • Biophysics
  • Materials Science (miscellaneous)
  • Mathematical Physics
  • Physics and Astronomy(all)
  • Physical and Theoretical Chemistry


Dive into the research topics of 'LhARA: The Laser-hybrid Accelerator for Radiobiological Applications'. Together they form a unique fingerprint.

Cite this